2017 Chia Tai Tianqing, Hengrui, Qilu, who to see in 2018?

In 2017, with China's formal accession to the ICH, the formal implementation of the new measures for the administration of drug registration, and the official launch of the opinions on deepening the reform of the review and approval system to encourage the innovation of pharmaceutical medical devices, pharmaceutical innovation and integration into the international community have become the direction of efforts, and the confidence and determination of regulatory authorities and pharmaceutical enterprises have become more and more firm In this context, the second "2017 China Pharmaceutical Summit Forum and top 100 research and development strength list of pharmaceutical enterprises" jointly sponsored by yaozhi.com and China Pharmacy magazine Co., Ltd aims at the development of current policies, industries, scientific research, markets, etc., to transfer new methods, open innovative ideas, tackle new technologies, and boost domestic enterprises to be unique in the whole pharmaceutical industry chain of China, and to be in China The international market will compete with international enterprises as soon as possible At the same time, the 2017 top 100 list of China's pharmaceutical R & D comprehensive strength released attracted giant enterprises represented by Hengrui, Zhengda Tianqing and Fosun to receive the award (attached with the 2017 list) in 2018, while continuing to encourage the development of innovative drugs, the State Council issued relevant policies to fully encourage the development of generic drugs in terms of promoting the research and development of generic drugs, improving the quality and efficacy of generic drugs, and ensuring the supply of generic drugs Generic drugs were once again put on the main stage of pharmaceutical development At this time, the third "2018 China Pharmaceutical R & D Innovation Summit and top 100 research and development strength of pharmaceutical enterprises" was born under the theme of "research and development of generic drugs in the new era", under the guidance of China Pharmaceutical University, Chongqing Municipal Economic and Information Commission, and sponsored by pharma.com and China Pharmacy magazine The conference will gather industry leaders, senior experts and scholars to give advice and suggestions for the development of generic drugs in the new era Academician of Chinese Academy of engineering, professor and doctoral supervisor of Fudan University, academician Chen Fener, partner and chief technology officer (CSO) of sanophytgmbh & Co.KG, member of USP / Expert Committee on dietary supplements and plant drugs, member of vitafoods European administrative advisory committee, Dr Joerg Gruenwald of Germany, vice president and doctoral supervisor of China Pharmaceutical University, Professor Lu Tao, etc will all be here At that time, under the guidance of China Pharmaceutical University, the top 100 of 2018 China Pharmaceutical R & D comprehensive strength ranking jointly created by the expert committee of pharmaceutical R & D strength ranking, the Organizing Committee of 2018 China Pharmaceutical R & D Innovation Summit, China Pharmacy and pharmaceutical intelligence network will be released On June 29, 2018, we will be together in Chongqing! Top 100 list of 2017 China's pharmaceutical R & D comprehensive strength